» Articles » PMID: 32761324

Medical Management and Prevention of Motor Complications in Parkinson's Disease

Overview
Specialty Neurology
Date 2020 Aug 8
PMID 32761324
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Levodopa is the most effective medication for the treatment of the motor symptoms of Parkinson's disease. However, over time, the clinical response to levodopa becomes complicated by a reduction in the duration and reliability of motor improvement (motor fluctuations) and the emergence of involuntary movements (levodopa-induced dyskinesia). Strategies that have been attempted in an effort to delay the development of these motor complications include levodopa sparing and continuous dopaminergic therapy. Once motor complications occur, a wide array of medical treatments is available to maximize motor function through the day while limiting dyskinesia. Here, we review the clinical features, epidemiology, and risk factors for the development of motor complications, as well as strategies for their prevention and medical management.

Citing Articles

An Unusual Presentation of Respiratory Dysfunction in Parkinson's Disease: A Case Study.

Rundquist L, Lyons S, Moljo R, Blavo C Cureus. 2025; 17(1):e77101.

PMID: 39917160 PMC: 11802192. DOI: 10.7759/cureus.77101.


Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives.

Yadav V, Dhanasekaran S, Choudhary N, Nathiya D, Thakur V, Gupta R Front Med (Lausanne). 2025; 12:1535682.

PMID: 39911864 PMC: 11794224. DOI: 10.3389/fmed.2025.1535682.


Potential Biomarkers and Treatment of Neuroinflammation in Parkinson's Disease.

Zhao Z, Fu Q, Guo X, He H, Yang G Actas Esp Psiquiatr. 2025; 53(1):181-188.

PMID: 39801407 PMC: 11726199. DOI: 10.62641/aep.v53i1.1779.


Injectable Hierarchical Bioactive Hydrogels with Fibroblast Growth Factor 21/Edaravone/Caffeic Acid Asynchronous Delivery for Treating Parkinson's Disease.

Xu J, Dai P, Zhang C, Dong N, Li C, Tang C Adv Sci (Weinh). 2024; 12(4):e2412020.

PMID: 39630931 PMC: 11775539. DOI: 10.1002/advs.202412020.


Efficacy of repetitive transcranial magnetic stimulation combined with peripheral magnetic stimulation on movement symptom and exploration of the optimal population in Parkinson's disease: A randomized controlled trial.

Sun P, Li J, Shen H, Jiang Y, Wang X, Xu T Medicine (Baltimore). 2024; 103(48):e40689.

PMID: 39612411 PMC: 11608732. DOI: 10.1097/MD.0000000000040689.


References
1.
Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View

2.
Chou K, Stacy M, Simuni T, Miyasaki J, Oertel W, Sethi K . The spectrum of "off" in Parkinson's disease: What have we learned over 40 years?. Parkinsonism Relat Disord. 2018; 51:9-16. DOI: 10.1016/j.parkreldis.2018.02.001. View

3.
Jankovic J . Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005; 20 Suppl 11:S11-6. DOI: 10.1002/mds.20458. View

4.
Hauser R, FRIEDLANDER J, Zesiewicz T, Adler C, Seeberger L, OBRIEN C . A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000; 23(2):75-81. DOI: 10.1097/00002826-200003000-00003. View

5.
Aquino C, Fox S . Clinical spectrum of levodopa-induced complications. Mov Disord. 2014; 30(1):80-9. DOI: 10.1002/mds.26125. View